Insights & Resources

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

KPMG has released their 2024 biopharma report detailing the challenges and opportunities for pharma companies moving forward into the new year.

For venture capital fund managers, understanding the Qualified Small Business Stock (QSBS) exemption presents a lucrative opportunity. Learn more in this overview.

Investment funds face complex state compliance challenges, including withholding obligations, pass-through taxes and multistate filing requirements.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

Owners of management companies must often choose between S-corporations and LLCs for pass-through taxes. Here's a comparison to know the difference.

Southern California’s real estate market is shifting toward multiuse developments, driven by urbanization, sustainability trends and zoning reforms.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

California tax rules for partnerships and LLCs are complex, with strict obligations for business structures, annual taxes and compliance requirements.

Blocker entities can help fund managers attract tax-exempt and non-U.S. investors, preserve tax profiles and navigate financial and tax reporting.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.